TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05865288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with the nursing staff supervising for proper administration of substance, after training and guiding the patient, and for supervision of side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with the nursing staff supervising for proper administration of substance, after training and guiding the patient, and for supervision of side effects.
Study: NCT05719155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D150
Description: 3 tablet coadministration under fed condition
Study: NCT06166199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT combined with resistance training
Description: Patients with SLE will undergo supervised HIIT on an ergometercycle, 4 x 4 minutes interval, (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week.~Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week.
Study: NCT05999292

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-R8760 injection at pre-defined dose levels
Description: PET/CT imaging at predefined timepoints

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-R8760 injection
Description: PET/CT imaging at a single timepoint
Study: NCT02211287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Comfort Care at the End of Life for Persons with Dementia'
Description: A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q\&A form and can help answer frequent family questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project Nurse - ACP Facilitator
Description: A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
Study: NCT06552637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synchronized Diaphragmatic Stimulation
Description: Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Synchronized Diaphragmatic Stimulation
Description: Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
Study: NCT04911361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
Study: NCT04811495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: A treatment plan is carried out which aims to improve pain, muscle balance and range of motion of the temporomandibular joint.
Study: NCT05021146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care and topical essential copaiba oil
Description: All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care and topical essential copaiba oil
Description: All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care and placebo treatment
Description: All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay.
Study: NCT05984602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: 125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
Study: NCT04896281

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylalanine-free milk
Description: Once a plasma PHE level of ≥ 95 μM is noted, phenylalanine-free diet (Phenex-2®, Abbott Nutrition, Ohio, USA; or Phenyl-Free 2®, Mead Johnson Nutrition, Minnesota, USA) is started as the only nutrition source for enteral feeding, as per the recommendation of dieticians, in the following 4 days. The phenylalanine-free diet is free of PHE but is enriched with protein, potassium, tyrosine, and antioxidant micronutrients. After the completion of the study, diet will be back to normal diet for all patients.
Study: NCT04798664

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Removal of Financial Barriers
Description: Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Removal of Financial Barriers
Description: Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Removal of Financial Barriers
Description: Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentives
Description: Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentives
Description: Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Health Application
Description: Episodic future thinking tool to overcome temporal discounting of future
Study: NCT05806450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition
Description: Psychoeducation about basic sleep structure and sleep hygiene
Study: NCT05704933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a monoclonal antibody o PD-1 protein, which is normally express on the surface of activated T cells. The interaction of PD-1 with its ligand (PD-L1) on T cells decreases their cytotoxic activity, helping protect normal cells in the setting of chronic inflammation. Tumor cells can utilize mechanisms to evade T cell mediated cytotoxicity by expressing PD-L1 on their surface or on the surface of T cells. Nivo, by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, allows T cells to remain active.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a recombinant, human antibody to CTLA-4.\[18-20\] CTLA-4 regulates T cell activation by binding with CD80 or CD86 with higher affinity than CD28, resulting in blockage of the co-stimulation signal and preventing further T cell activation. Blockade of CTLA-4 results in further T cell activation.
Study: NCT06251856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lymphedema education program
Description: On post-op day 2, patients will receive Symptom Management Model-Based Lower Extremity Lymphedema Training. Brochures will be introduced and delivered to the patient.
Study: NCT05704933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: Opdualag (Nivolumab and Relatlimab-rmbw) is a human monoclonal antibody to LAG-3, currently under investigation.\[6\] Relatlimab is an antibody (IgG4 isotype) that has a stabilizing hinge mutation for attenuated Fc receptor binding to decrease or get rid of the possibility of antibody-mediated and/or complement-mediated target cell killing. Rela binds to an epitope on LAG-3 with high affinity and specificity, with subsequent blockade of LAG-3 and its interaction with its ligand, MHC class II. This antibody displays compelling in vitro functional activity in reversing LAG-3 that facilitates inhibition of an antigen-specific murine T cell hybridoma overexpressing human LAG-3 . Relatlimab was also shown to improve the activation of human T cells in superantigen stimulation assays when added either alone or in combination with Nivolumab.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Craniotomy
Description: Participants will undergo craniotomy for surgical resection of melanoma brain metastases.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Craniotomy
Description: Participants will undergo craniotomy for surgical resection of melanoma brain metastases.
Study: NCT05930210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENERGI-F703 GEL
Description: Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ENERGI-F703 matched vehicle
Description: Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
Study: NCT06269484

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)
Description: placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan + placebo (placebo matching dapagliflozin tablet)
Description: zibotentan capsule~placebo tablet (matching dapagliflozin tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan + dapagliflozin
Description: zibotentan capsule~dapagliflozin 10 mg tablet
Study: NCT05221840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Monalizumab IV (intravenous infusion)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV (intravenous infusion)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo IV (intravenous infusion)
Study: NCT06538610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter monitor
Description: Holter monitor fitted from start of 5-FU infusion (Day 1) to 5-FU infusion ending (Day 3).~Holter monitor to be worn for approximately 46-48 hours.
Study: NCT04738123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study: NCT05731726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplilumab
Description: Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w.~For the timing of serplulimab, there is a subgroup developed, all enrolled patients will be divided into 2 subgroups in 1:1 ratio, the fasting group and the control group. For the fasting group patients, fasting starts from 8 p.m. the day before treatment and concludes at 12 p.m. on the treatment day, water is allowed. For the control group patients, they have meals according to their habits.
Study: NCT05001243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac
Description: PBOHB to improve uncorrected near vision in healthy presbyopic patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac
Description: PBOHB to improve uncorrected near vision in healthy presbyopic patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Hydrochloride
Description: Apply in the fellow eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: Apply in the fellow eye
Study: NCT04951934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmoLED
Description: This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the wound has a greater extension than the irradiated area, multiple repeated applications will be performed on adjacent areas, until the entire wound is covered.
Study: NCT05731726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT04951934

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging.
Study: NCT05651464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycine
Description: Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
Study: NCT05731726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celebrex
Study: NCT06248216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relievrx
Description: The RelieVRx program is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Audio Mp4
Description: Audio Mp4 modules ranging from 3-15 minutes with guided meditation.
Study: NCT05818774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning
Description: Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae
Description: Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets.
Study: NCT06372444

Intervention type: RADIATION
Intervention: Positron emission tomography (PET)
Description: Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT

Intervention type: RADIATION
Intervention: Positron emission tomography (PET)
Description: Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT
Study: NCT05949177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Exposure and Mindfulness Meditation
Description: Participants will complete graded exposure and will be encouraged to face fear-eliciting situations. Participants will also complete mindfulness meditation guided through the Headspace mobile application. Participants will complete the graded exposure one time per week and will complete the mindfulness meditation 4 times per week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Control
Description: Participants will receive an email stating that they will receive access to 5-weeks of Headspace after 5-weeks. Participants will be also asked to not change their normal routines or download apps for relaxation, meditation, or sleep during 5-weeks. After completion of the outcome assessments at 5-weeks, participants in this group will receive access to 5-weeks of Headspace.
Study: NCT05566795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Oral type II RAF kinase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapeutic Agent
Description: Intravenous solution for injection
Study: NCT04948697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: 900 mg intravenously once every 3 weeks (dosed in 21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenously once every 3 weeks (dosed in 21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
Study: NCT06067165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POET feeling
Description: POET is adapted from online Emotion Regulation Individual Therapy for Adolescents developed by the research group (ClinicalTrials.gov Identifier: NCT03353961).~POET is also based on the Modal model of emotion and Process model of emotion regulation that provides a framework for understanding how emotions are generated, experienced and how they can be regulated. The youth component of POET will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective support and responding to their adolescent's and their own emotions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive treatment
Description: The treatment will include educative material on mental health and self-reflection on themes such as school, family and friends. The parent component will include educative material and self reflection in how to support their adolescent.